Neurodegenerative Disease Management

1.9(top 20%)

impact factor

577(top 50%)

papers

6.5K(top 20%)

citations

35(top 20%)

h-index

2.1(top 20%)

impact factor

719

all documents

7.1K

doc citations

55(top 20%)

g-index

Top Articles

#	Title	Journal	Year	Citations
1	Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis	Neurodegenerative Disease Management	2019	168
2	Prevention of falls in Parkinson's disease: a review of fall risk factors and the role of physical interventions	Neurodegenerative Disease Management	2014	151
3	Activities of daily living: where do they fit in the diagnosis of Alzheimer’s disease?	Neurodegenerative Disease Management	2012	129
4	Parkinson's disease psychosis: presentation, diagnosis and management	Neurodegenerative Disease Management	2017	126
5	The sleep–wake cycle and Alzheimer's disease: what do we know?	Neurodegenerative Disease Management	2014	118
6	When dementia progresses quickly: a practical approach to the diagnosis and management of rapidly progressive dementia	Neurodegenerative Disease Management	2014	92
7	Brain insulin resistance in Alzheimer’s disease and its potential treatment with GLP-1 analogs	Neurodegenerative Disease Management	2014	90
8	The global prevalence of Huntington's disease: a systematic review and discussion	Neurodegenerative Disease Management	2016	88
9	Collaborative transdisciplinary team approach for dementia care	Neurodegenerative Disease Management	2014	87
10	Frontotemporal dementia: diagnosis, deficits and management	Neurodegenerative Disease Management	2014	86
11	Traumatic brain injury as a risk factor for Alzheimer's disease: current knowledge and future directions	Neurodegenerative Disease Management	2016	79
12	Managing juvenile Huntington’s disease	Neurodegenerative Disease Management	2013	78
13	Review of ‘the potential role of arterial stiffness in the pathogenesis of Alzheimer's disease’	Neurodegenerative Disease Management	2015	75
14	Depression in the early stages of Huntington disease	Neurodegenerative Disease Management	2011	74
15	Ultraviolet radiation, vitamin D and multiple sclerosis	Neurodegenerative Disease Management	2015	71
16	Behavioral treatments for speech in Parkinson's disease: meta-analyses and review of the literature	Neurodegenerative Disease Management	2015	66
17	Speech disorders in Parkinson's disease: pathophysiology, medical management and surgical approaches	Neurodegenerative Disease Management	2018	66
18	Dementia: stigma and its effects	Neurodegenerative Disease Management	2012	62
19	Double-blind, randomized and controlled trial of EPI-743 in Friedreich's ataxia	Neurodegenerative Disease Management	2018	62
20	The role of oligodendroglial dysfunction in amyotrophic lateral sclerosis	Neurodegenerative Disease Management	2014	61
21	Electroconvulsive therapy for depression in Parkinson's disease: systematic review of evidence and recommendations	Neurodegenerative Disease Management	2016	61
22	Role of epigenetics in Alzheimer's disease pathogenesis	Neurodegenerative Disease Management	2018	60
23	Testing family-centered, function-focused care in hospitalized persons with dementia	Neurodegenerative Disease Management	2015	59
24	Emerging therapies in Friedreich's ataxia	Neurodegenerative Disease Management	2016	55
25	Neurological disability and its association with walking impairment in multiple sclerosis: brief review	Neurodegenerative Disease Management	2014	53
26	Light, sleep and circadian rhythms in older adults with Alzheimer's disease and related dementias	Neurodegenerative Disease Management	2017	51
27	Corrigendum	Neurodegenerative Disease Management	2016	50
28	The biomarker and therapeutic potential of miRNA in Alzheimer's disease	Neurodegenerative Disease Management	2015	49
29	Amyloid imaging, risk disclosure and Alzheimer’s disease: ethical and practical issues	Neurodegenerative Disease Management	2013	48
30	Essential tremor is not a neurodegenerative disease	Neurodegenerative Disease Management	2012	47
31	Clinical pharmacology review of safinamide for the treatment of Parkinson’s disease	Neurodegenerative Disease Management	2015	45
32	Alcohol-related cognitive impairment: current trends and future perspectives	Neurodegenerative Disease Management	2016	45
33	Evaluation of rivastigmine in Alzheimer's disease	Neurodegenerative Disease Management	2021	45
34	Lifestyle-based modifiable risk factors in multiple sclerosis: review of experimental and clinical findings	Neurodegenerative Disease Management	2019	41
35	The impact of multiple sclerosis on family members: a review of the literature	Neurodegenerative Disease Management	2014	38
36	Nondopaminergic treatments for Parkinson's disease: current and future prospects	Neurodegenerative Disease Management	2016	38
37	The relationship between hyperhomocysteinemia and neurodegeneration	Neurodegenerative Disease Management	2016	38
38	Management of speech, language and communication difficulties in Huntington’s disease	Neurodegenerative Disease Management	2012	37
39	Prognostic significance of weight changes in Parkinson's disease: the Park–weight phenotype	Neurodegenerative Disease Management	2014	37
40	Breathing new life into treatment advances for respiratory failure in amyotrophic lateral sclerosis patients	Neurodegenerative Disease Management	2014	36
41	Telehealth for the cognitively impaired older adult and their caregivers: lessons from a coordinated approach	Neurodegenerative Disease Management	2021	36
42	A qualitative review of instrumental activities of daily living in dementia: what's cooking?	Neurodegenerative Disease Management	2014	35
43	Alzheimer's disease: the potential therapeutic role of the natural antibiotic amyloid-β peptide	Neurodegenerative Disease Management	2016	35
44	Functional cognitive disorders: demographic and clinical features contribute to a positive diagnosis	Neurodegenerative Disease Management	2018	35
45	Neuropsychiatric symptoms in primary progressive aphasia: phenomenology, pathophysiology, and approach to assessment and treatment	Neurodegenerative Disease Management	2013	33
46	Application of the ‘5-2-1’ screening criteria in advanced Parkinson’s disease: interim analysis of DUOGLOBE	Neurodegenerative Disease Management	2020	33
47	Oral feeding in Huntington’s disease: a guideline document for speech and language therapists	Neurodegenerative Disease Management	2012	32
48	Clinical insights into use of apomorphine in Parkinson's disease: tools for clinicians	Neurodegenerative Disease Management	2014	32
49	Managing cognition in progressive supranuclear palsy	Neurodegenerative Disease Management	2016	32
50	Management of glaucoma as a neurodegenerative disease	Neurodegenerative Disease Management	2017	32

Scientometrics

Overviews

Citing Bodies

Neurodegenerative Disease Management

Top Articles